File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Asia‐Pacific Leukemia Consortium: An innovative and collaborative initiative to improve care of leukemia and related diseases in the Asia‐Pacific region

TitleAsia‐Pacific Leukemia Consortium: An innovative and collaborative initiative to improve care of leukemia and related diseases in the Asia‐Pacific region
Authors
KeywordsAsia-Pacific
burden
collaboration
leukemia
status quo
Issue Date1-Jun-2023
PublisherWiley
Citation
Asia-Pacific Journal of Clinical Oncology, 2023, v. 19, n. 6, p. 655-663 How to Cite?
Abstract

The burden of leukemia and related diseases is rapidly growing in Asia. Currently, there is a paucity of regional collaborative groups/initiatives that focus exclusively on the management of leukemia in the Asia-Pacific (APAC) region. The Asia-Pacific Leukemia Consortium (APLC) was established on the 8 September 2021 to understand the status quo, unmet needs, and ways to improve the management of leukemia and related diseases in the APAC region. The APLC working group set up a group of experts from various countries (Singapore, Malaysia, Thailand, Hong Kong, Japan, South Korea, Taiwan, China, and Australia) to discuss on the status of: (i) clinical trials; (ii) disease registry database; (iii) genetic and tissue repository; (iv) patient advocacy and care; and (v) disease prevention and education in the APAC region. Low levels of awareness about leukemia amongst the public, lack of financial support, and limited access to newly approved therapies were identified as barriers to the implementation of effective leukemia management in low- or mid-income Asian countries. Patients often enroll in clinical trials to gain access to novel/approved therapies. The APLC group aims to address the growing threat of leukemia through a collaborative approach to advance disease prevention, research, clinical trials, and education.


Persistent Identifierhttp://hdl.handle.net/10722/338564
ISSN
2023 Impact Factor: 1.4
2023 SCImago Journal Rankings: 0.531
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLao, Zhentang-
dc.contributor.authorTse, Eric Wai Choi-
dc.contributor.authorChuncharunee, Suporn-
dc.contributor.authorKwong, Yok Lam-
dc.contributor.authorWei, Andrew-
dc.contributor.authorKo, Bor Sheng-
dc.contributor.authorKim, Jin Seok-
dc.contributor.authorNg, Soo Chin-
dc.contributor.authorWang, Jianxiang-
dc.contributor.authorGoh, Yeow Tee-
dc.date.accessioned2024-03-11T10:29:50Z-
dc.date.available2024-03-11T10:29:50Z-
dc.date.issued2023-06-01-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology, 2023, v. 19, n. 6, p. 655-663-
dc.identifier.issn1743-7555-
dc.identifier.urihttp://hdl.handle.net/10722/338564-
dc.description.abstract<p>The burden of leukemia and related diseases is rapidly growing in Asia. Currently, there is a paucity of regional collaborative groups/initiatives that focus exclusively on the management of leukemia in the Asia-Pacific (APAC) region. The Asia-Pacific Leukemia Consortium (APLC) was established on the 8 September 2021 to understand the status quo, unmet needs, and ways to improve the management of leukemia and related diseases in the APAC region. The APLC working group set up a group of experts from various countries (Singapore, Malaysia, Thailand, Hong Kong, Japan, South Korea, Taiwan, China, and Australia) to discuss on the status of: (i) clinical trials; (ii) disease registry database; (iii) genetic and tissue repository; (iv) patient advocacy and care; and (v) disease prevention and education in the APAC region. Low levels of awareness about leukemia amongst the public, lack of financial support, and limited access to newly approved therapies were identified as barriers to the implementation of effective leukemia management in low- or mid-income Asian countries. Patients often enroll in clinical trials to gain access to novel/approved therapies. The APLC group aims to address the growing threat of leukemia through a collaborative approach to advance disease prevention, research, clinical trials, and education.</p>-
dc.languageeng-
dc.publisherWiley-
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAsia-Pacific-
dc.subjectburden-
dc.subjectcollaboration-
dc.subjectleukemia-
dc.subjectstatus quo-
dc.titleAsia‐Pacific Leukemia Consortium: An innovative and collaborative initiative to improve care of leukemia and related diseases in the Asia‐Pacific region-
dc.typeArticle-
dc.identifier.doi10.1111/ajco.13970-
dc.identifier.scopuseid_2-s2.0-85161436252-
dc.identifier.volume19-
dc.identifier.issue6-
dc.identifier.spage655-
dc.identifier.epage663-
dc.identifier.eissn1743-7563-
dc.identifier.isiWOS:000998394200001-
dc.identifier.issnl1743-7555-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats